{"denoms":[{"counts":[{"groupId":"BG000","value":"14"}],"units":"Participants"}],"groups":[{"description":"Patients receive FR901228 (depsipeptide) IV at 13 mg/m2 over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nromidepsin: Given IV","id":"BG000","title":"Treatment (Romidepsin)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"46","upperLimit":"75","value":"59.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Hispanic"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"}]}